Apellis Pharmaceuticals Inc (1JK)

Currency in EUR
16.03
-0.35(-2.14%)
Closed·
Unusual trading volume
Fair Value
Day's Range
16.0323.00
52 wk Range
14.6039.00
Key Statistics
Bid/Ask
16.33 / 16.50
Prev. Close
16.16
Open
19.95
Day's Range
16.03-23
52 wk Range
14.6-39
Volume
6.54K
Average Volume (3m)
901
1-Year Change
-53.79%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1JK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Apellis Pharmaceuticals Inc Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Compare 1JK to Peers and Sector

Metrics to compare
1JK
Peers
Sector
Relationship
P/E Ratio
0.0x−4.6x−0.5x
PEG Ratio
0.00−0.150.00
Price/Book
0.0x3.7x2.6x
Price / LTM Sales
0.0x12.8x3.2x
Upside (Analyst Target)
0.0%117.0%42.0%
Fair Value Upside
Unlock6.4%6.6%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

1JK Income Statement

People Also Watch

60.26
MP
-6.01%
25.53
CNC
-4.95%
53.090
ASTS
-2.08%
17.670
QBTS
-3.71%

FAQ

What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?

Apellis Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Apellis Pharmaceuticals Inc?

The stock symbol for Apellis Pharmaceuticals Inc is "1JK."

What Is the Apellis Pharmaceuticals Inc Market Cap?

As of today, Apellis Pharmaceuticals Inc market cap is 2.05B.

What Is Apellis Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Apellis Pharmaceuticals Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 1JK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Apellis Pharmaceuticals Inc Stock Split?

Apellis Pharmaceuticals Inc has split 0 times.

What is the current trading status of Apellis Pharmaceuticals Inc (1JK)?

As of 30 Jul 2025, Apellis Pharmaceuticals Inc (1JK) is trading at a price of 16.03, with a previous close of 16.16. The stock has fluctuated within a day range of 16.03 to 23.00, while its 52-week range spans from 14.60 to 39.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.